Reveal Therapies, Inc.

The Problem

Cancer killed over 7.6 million people in 2007, accounting for 13% of all deaths worldwide.  This year, more than 12 million individuals worldwide, including 3 million living in the United States, will contract the disease. The average individual’s lifetime risk is approximately 1 in 2.  In the US alone, in 2005, the NIH estimated $75 billion was spent directly on cancer care. Total cancer care costs in the U.S. are estimated at more than $210 billion per year. Cancer remains an unresolved and expensive problem in both human and financial terms.

The Solution(s)

Reveal Therapies, Inc., has identified a synergistic and cost-effective treatment path based on a medical device technology platform that can consistently provide multi-year remissions from cancer at very high efficacy rates, while simultaneously delivering much higher quality of life to the patient during and after treatment. This medical device platform is designed to improve the functioning of the immune system through the manipulation of cells and chemical messengers at a level of control that cannot be achieved by drugs alone. Reveal’s approach and effectiveness will change cancer from a death sentence to a manageable, chronic condition for more than half of the effected populations.

While main stream science has tended to focus on products that will attack cancers, whether by attacking the cancer cells directly (chemotherapy, radiation, surgery), or by destroying the vascular system that supports the cancer mass (angiogenesis), Reveal has a complimentary approach. Other therapies involve an attempt at bolstering the immune system with supplements and/or nutraceuticals. The results of these discoveries have reduced cancer mortality, though none have been able to claim the ability to “cure” cancer. The market is therefore best described as combinations of complimentary therapies.

The Company’s products focus on how cancers defeat the immune system and deal directly with cancer-fabricated, false signals. It does so in four different ways:

1. By directly removing false receptors (created by cancer cells that bind to the immune system’s cancer cell killers)

2. By isolating immune system cells that exist to identify, create destroying solutions, and ultimately destroy cancers into an enriching environment so that these cells can grow in potency and volume,

3. Then returning properly amplified cells to the patient, and

4. By removing toxins that are part of the aggressive cancer growth and therapies. The entire process can be best described as Subtractive Therapy where biologicals fabricated by cancers and toxins that follow are removed.

The removal or isolation of healthy cells that are the targets of the cancer cell’s panoply of misdirections so that they may multiply in number and effectiveness is also a component of Subtractive Therapy. In summary: Subtractive Therapy is the process of introducing an agent that is exactly or is sufficiently similar to the immune system resource targeted by a disease, to remove the molecules synthesized by the disease that defeat the immune system.

The Opportunity

Reveal Therapies, Inc., has a synergistic and cost-effective treatment path, which is based on a medical device technology platform that can provide multi-year remissions from cancer at a reasonable price while also delivering much higher quality of life to the patient during and after treatment. This medical device platform is designed to improve the functioning of the immune system through the manipulation of cells and chemical messengers at a level of control that cannot be achieved by drugs alone.  As a medical device therapy, the path to approval is more than ten times cheaper and three times faster than the average drug approval process. Time to market is estimated at no longer than 3 years, and most likely less than 18 months. Given current trends, Reveal Therapies estimates that every percentage point of market share represents almost $1 billion in revenue. These revenue estimates are for the United States alone, globally, this number will be much larger. Reveal’s approach and effectiveness will change cancer from a death sentence to a manageable, chronic condition for more than half of the effected populations.

Reveal has discovered how to participate in the cancer treatment and therapy market by providing substantial value as an adjunctive therapy (though the Company anticipates delivering a greater cost/benefit solution to conventional therapy as a standalone treatment) that requires substantially less development and production cost, complimentary to current cancer therapies. Each new discovery, that has undergone the rigors of the FDA gauntlet and manages to achieve at least a 1% improvement in life extension, captures approximately $1 billion in market value. Though the rewards are great, so are the costs of discovery, clinical trials and validation, and marketing and sales costs that achieve these market valuations. Given that Reveal’s therapies are likely to consistently provide multi-year remissions from broad spectrum of solid cancers at very high efficacy rates, while simultaneously delivering much higher quality of life to the patient during and after treatment, conservative estimates for penetration into the cancer markets are between 3% and 8% by our 5^th year, and 2% to 3% additional market share for the next 5 subsequent years.

The Company

Reveal Therapies (also Reveal, Inc., the “Company”), is a clinical marketing, training and distribution company of unique cancer defeating technologies and therapies. The Company owns world-wide exclusive marketing rights to three products designed at the Company’s Reveal Therapies Foundation (aka the Center for Open Source Technology Therapies, the “Center”.) The Center is a 501C3 organization whose purpose is to improve quality of life by:

1. Operating a unique research and development team to originate and vet new discoveries,

2. Providing open source access to inventive and innovative products, and

3. Channeling benevolent contributions to people in need.

The Company expects to have its products in validation studies by mid 2010 and in revenues by Q4 2010. The Company’s offerings consist of products that are standalone therapies or products that enhance the performance of currently approved cancer treatment therapies.

Contacting Us

Reveal Therapies, Inc., P.O. Box 6128, San Diego, CA 92166 – help@revealtherapies.com